Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
SEDAPAP vs AXOTAL
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
SEDAPAP is a combination of an opioid agonist (acetaminophen, hydrocodone) and a non-opioid analgesic. Hydrocodone acts as a mu-opioid receptor agonist, inhibiting ascending pain pathways and altering pain perception. Acetaminophen inhibits cyclooxygenase (COX) enzymes in the central nervous system, reducing prostaglandin synthesis and providing analgesia and antipyresis.
Axotal contains butalbital, a barbiturate that enhances GABA-A receptor activity, and acetaminophen, an analgesic and antipyretic whose mechanism is not fully understood but may involve COX inhibition and activation of descending serotonergic pathways.
Management of moderate to moderately severe pain where an opioid analgesic is required
Tension headache
1-2 tablets (acetaminophen 325 mg/butalbital 50 mg/caffeine 40 mg) orally every 4 hours as needed; maximum 6 tablets per day.
Each tablet: butalbital 50 mg, acetaminophen 300-500 mg, caffeine 40 mg. 1-2 tablets orally every 4 hours as needed, not exceeding 6 tablets per day.
The terminal elimination half-life is approximately 4-6 hours in adults with normal renal function. In patients with creatinine clearance <30 m L/min, the half-life may be prolonged to 10-15 hours, requiring dose adjustment.
Terminal elimination half-life is 2-4 hours in patients with normal renal function; prolonged to 8-12 hours in severe renal impairment (Cr Cl <30 m L/min).
Hydrocodone is metabolized primarily via CYP3A4 and CYP2D6 to hydromorphone and other metabolites. Acetaminophen is metabolized primarily via glucuronidation and sulfation; a minor pathway via CYP2E1 produces a hepatotoxic metabolite (NAPQI) that is normally detoxified by glutathione.
Butalbital is metabolized primarily by CYP2C19; acetaminophen is metabolized mainly via glucuronidation by UGT1A1 and UGT1A6, sulfation by SULT1A1, and minor oxidation by CYP2E1.
Renal excretion of unchanged drug accounts for approximately 60-70% of the administered dose. Hepatic metabolism to inactive metabolites, followed by biliary and fecal elimination, accounts for the remaining 30-40%. Less than 5% is excreted unchanged in feces.
Renal excretion of unchanged drug (60-70%) and glucuronide conjugates (10-20%); biliary excretion (5-10%); fecal elimination (<10%).
Approximately 92-95% bound to serum albumin, with minor binding to alpha-1-acid glycoprotein.
98-99% bound primarily to albumin; minor binding to alpha-1-acid glycoprotein.
Volume of distribution is 0.8-1.2 L/kg, indicating extensive distribution into total body water and tissues. Higher Vd is observed in obesity (up to 1.5 L/kg).
0.15-0.25 L/kg, indicating distribution mainly in extracellular fluid and limited tissue penetration.
Oral: 75-85% due to first-pass metabolism. Intramuscular: 90-100%. Intravenous: 100%.
Oral: 85-95%; intramuscular: 90-100%; intravenous: 100%.
GFR 30-50 m L/min: Use with caution, maximum 4 tablets per day. GFR <30 m L/min: Contraindicated due to butalbital accumulation.
No specific guidelines; contraindicated in severe renal impairment (Cr Cl <30 m L/min). Use with caution in mild-moderate impairment due to acetaminophen and butalbital accumulation.
Child-Pugh A: No adjustment. Child-Pugh B: Reduce dose by 50%, maximum 3 tablets per day. Child-Pugh C: Contraindicated.
Contraindicated in Child-Pugh Class C (severe hepatic impairment). In Child-Pugh A or B, reduce dose or extend interval; maximum acetaminophen 2000 mg/day, avoid butalbital if possible.
Not recommended for patients under 12 years of age.
Not recommended for children under 12 years. For ages 12-18: same as adult dose (1-2 tablets) but limit to 4 tablets per day and monitor for sedation.
Initiate at lowest effective dose (1 tablet every 6 hours); monitor for excessive sedation and cognitive impairment.
Start at lower dose (1 tablet every 6 hours) due to increased sensitivity to butalbital (c NS depression, falls) and acetaminophen hepatotoxicity risk; limit to 4 tablets per day, avoid in frail elderly.
Addiction, Abuse, and Misuse: SEDAPAP exposes users to risks of opioid addiction, abuse, and misuse, which can lead to overdose and death. Assess patient's risk before prescribing and monitor regularly. Life-Threatening Respiratory Depression: Serious, life-threatening, or fatal respiratory depression may occur. Monitor closely, especially during initiation and dose titration. Accidental Ingestion: Accidental ingestion of even one dose, especially by children, can cause fatal overdose. Neonatal Opioid Withdrawal Syndrome: Prolonged use during pregnancy can result in neonatal opioid withdrawal syndrome, which may be life-threatening. Cytochrome P450 3A4 Interaction: Concomitant use with CYP3A4 inhibitors may increase hydrocodone levels and prolong adverse effects. Concomitant use with CYP3A4 inducers may decrease efficacy. Risks from Concomitant Use with Benzodiazepines or Other CNS Depressants: Concomitant use may result in profound sedation, respiratory depression, coma, and death. Avoid use in patients with known or suspected gastrointestinal obstruction, including paralytic ileus.
Acetaminophen has been associated with cases of acute liver failure, sometimes resulting in liver transplant and death. Hepatotoxicity is usually associated with doses exceeding 4000 mg per day and often involves more than one acetaminophen-containing product.
Addiction, abuse, and misuse; life-threatening respiratory depression; accidental ingestion; neonatal opioid withdrawal syndrome; risks from concomitant use with benzodiazepines or other CNS depressants; severe hypotension; adrenal insufficiency; hepatotoxicity (due to acetaminophen); opioid-induced hyperalgesia; withdrawal; risks of use in patients with head injuries, impaired consciousness, or increased intracranial pressure; use in patients with gastrointestinal conditions including paralytic ileus; use in patients with severe renal or hepatic impairment; use in elderly, cachectic, or debilitated patients; use in patients with pulmonary disease; use in patients with biliary tract disease; use in patients with acute pancreatitis; use in patients with CNS depression; use in patients with toxic psychosis; use in patients with known or suspected surgical abdomen; use in patients with urinary retention; use in patients with prostatic hypertrophy; use in patients with urethral stricture; use in patients with hypothyroidism; use in patients with Addison's disease; use in patients with kyphoscoliosis; use in patients with severe obesity; use in patients with seizures or seizure disorders; use in patients with substance abuse history; driving and operating machinery; use in pregnancy; use in lactation.
Hepatotoxicity with acetaminophen overdose; risk of rhabdomyolysis, angioedema, Stevens-Johnson syndrome; butalbital dependence and withdrawal; CNS depression; impairment of mental or physical abilities; avoid concurrent alcohol use.
Hypersensitivity to hydrocodone, acetaminophen, or any component of the formulation; significant respiratory depression; acute or severe bronchial asthma in an unmonitored setting or in the absence of resuscitative equipment; known or suspected gastrointestinal obstruction, including paralytic ileus; concurrent use of monoamine oxidase inhibitors (MAOIs) or within 14 days of such therapy.
Hypersensitivity to barbiturates or acetaminophen; porphyria; severe hepatic impairment; respiratory depression; history of substance abuse.
Avoid alcohol. Take with food or milk to reduce gastrointestinal irritation. High-fat meals may delay absorption but not clinically significant. No specific food restrictions.
Avoid alcohol intake; concurrent use increases risk of acetaminophen hepatotoxicity. Grapefruit juice may increase caffeine levels; limit consumption. High-fat meals may delay absorption of butalbital. Maintain adequate hydration; caffeine has mild diuretic effect.
First trimester: Increased risk of neural tube defects and orofacial clefts (valproate component). Second and third trimesters: Fetal valproate syndrome (craniofacial abnormalities, cardiac defects, developmental delay), neonatal hemorrhage due to vitamin K deficiency (valproate), and withdrawal syndrome. Acetaminophen carries minimal risk.
Pregnancy Category D. First trimester: Risk of cardiovascular malformations (e.g., Ebstein anomaly), neural tube defects, and oral clefts increased with lithium exposure. Second and third trimesters: Increased risk of fetal/neonatal toxicity including cardiac arrhythmias, hypoglycemia, polyhydramnios, preterm birth, and neonatal goiter. Avoid if possible; weigh risks vs. benefits.
Both valproate and acetaminophen are excreted into breast milk. Valproate M/P ratio approximately 0.05-0.1; infant serum levels low but potential for hepatotoxicity and thrombocytopenia. Acetaminophen M/P ratio ~1.0, considered safe in therapeutic doses. Caution advised with valproate; monitor infant for jaundice, bruising, and sedation.
Lithium is excreted into human milk (M/P ratio 0.3-0.8). Breastfeeding is not recommended due to risk of neonatal toxicity (hypotonia, hypothermia, cyanosis, ECG changes). Monitor infant serum levels if breastfeeding is continued.
Valproate: Dose may need reduction due to increased clearance (plasma levels decrease 30-50% in late pregnancy); monitor serum levels and adjust to maintain therapeutic concentration. Acetaminophen: No dose adjustment required in pregnancy; standard dosing recommended.
Dose adjustments are often necessary due to increased glomerular filtration rate and expanded plasma volume. Monitor serum levels closely (every 2-4 weeks in second and third trimesters). Dose may need to be increased or given in divided doses (e.g., 3 times daily) due to faster clearance. Postpartum: reduce dose promptly to pre-pregnancy levels within 24 hours after delivery to avoid toxicity from narrowed volume of distribution.
SEDAPAP is a combination product containing an opioid (codeine or hydrocodone) and acetaminophen. Avoid exceeding 3 grams/day of acetaminophen to prevent hepatotoxicity. Monitor respiratory depression, especially in opioid-naive patients and those with sleep apnea. Use with caution in hepatic impairment, ethanol use disorder, and in patients on other CNS depressants. Administer with food to reduce GI upset.
AXOTAL (butalbital/acetaminophen/caffeine) is a combination analgesic for tension-type headaches. Butalbital is a barbiturate with addiction potential; limit use to less than 2 days per week to avoid medication overuse headache (MOH). Acetaminophen hepatic toxicity risk increases with chronic alcohol use or pre-existing liver disease. Caffeine may cause withdrawal headaches upon abrupt cessation.
Do not exceed recommended dose; too much acetaminophen can cause liver damage.,Avoid alcohol while taking this medication.,Do not combine with other acetaminophen-containing products.,May cause drowsiness or dizziness; avoid driving or operating machinery.,Take with food or milk if stomach upset occurs.,Report any difficulty breathing, severe constipation, or signs of liver injury (yellowing skin/eyes, dark urine) immediately.,Do not stop suddenly after prolonged use to avoid withdrawal symptoms.
Do not exceed 4 tablets per day to avoid acetaminophen overdose (max 4000 mg/day).,Avoid alcohol while taking this medication due to risk of liver damage.,This drug can be habit-forming; use only as prescribed for headache attacks, not for prophylaxis.,May cause drowsiness or dizziness; avoid driving or operating machinery until you know how you react.,Discontinue and seek medical help if you experience signs of liver injury (jaundice, dark urine) or allergic reaction (rash, swelling).,Caffeine content may interfere with sleep or exacerbate anxiety; limit other caffeine sources.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about SEDAPAP vs AXOTAL, answered by our medical review team.
SEDAPAP is a Barbiturate Combination Analgesic that works by SEDAPAP is a combination of an opioid agonist (acetaminophen, hydrocodone) and a non-opioid analgesic. Hydrocodone acts as a mu-opioid receptor agonist, inhibiting ascending pain pathways and altering pain perception. Acetaminophen inhibits cyclooxygenase (COX) enzymes in the central nervous system, reducing prostaglandin synthesis and providing analgesia and antipyresis.. AXOTAL is a Barbiturate Combination Analgesic that works by Axotal contains butalbital, a barbiturate that enhances GABA-A receptor activity, and acetaminophen, an analgesic and antipyretic whose mechanism is not fully understood but may involve COX inhibition and activation of descending serotonergic pathways.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between SEDAPAP and AXOTAL depend on the specific clinical indication. These are both Barbiturate Combination Analgesic agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of SEDAPAP is: 1-2 tablets (acetaminophen 325 mg/butalbital 50 mg/caffeine 40 mg) orally every 4 hours as needed; maximum 6 tablets per day.. The standard adult dose of AXOTAL is: Each tablet: butalbital 50 mg, acetaminophen 300-500 mg, caffeine 40 mg. 1-2 tablets orally every 4 hours as needed, not exceeding 6 tablets per day.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between SEDAPAP and AXOTAL in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. SEDAPAP is classified as Category C. First trimester: Increased risk of neural tube defects and orofacial clefts (valproate component). Second and third trimesters: Fetal valproate syndrome (craniofacial abnormalities. AXOTAL is classified as Category C. Pregnancy Category D. First trimester: Risk of cardiovascular malformations (e.g., Ebstein anomaly), neural tube defects, and oral clefts increased with lithium exposure. Second an. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.